May 23, 2023 4:59pm

It’s not good until it isn’t; does anyone truly know what’s going on –with the cell and gene therapy started slipping?

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN -231.07 points (-0.69%), the S&P closed DOWN -47.05 points (-1.12%) while the Nasdaq closed DOWN -160.53 points (-1.26%)

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies.

Indexes fell Tuesday as debt ceiling “talks” appeared to yield little progress ahead of the June 1 deadline to avoid a potentially disastrous default.

“I think a deal will be reached, but I worry that the chances of a default are greater than they ever have been.” <Republican Sen Ted Cruz, from Texas>

“We are sending a very negative signal about our ability to run our economy, let alone be an anchor for the rest of the world. The market so far has actually dealt with it very well.” As to the market’s stability, and views the S&P 500 as fairly priced despite this recent headwind and uncertainty surrounding the Federal Reserve’s next rate move. < Mohamed El-Erian, The Allianz chief economic advisor>

Economic Data Docket: The May reading for the Purchasing Managers Index (PMI) came in at 48.5. That was lower than the 50.0 consensus estimate, according to economists.

 

Tuesday (5/23) … RegMed Investors’ (RMi) pre-open: “what does one see or feel. Fatigue and uncertainty by “nothing” updates on debt ceiling matters and waiting for more concrete developments – which haven’t expressed any concreate progress.” …   https://www.regmedinvestors.com/articles/12971

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …

  • Tuesday’s advance/decline line opened positive at 28 up/ 7 down and 0 flat, stayed positive with 23 up/ 12 down and 0 flat at the mid-day, ending with a negative close of 17/18 and 0 flats
  • Monday’s advance/decline line opened positive at 29 up/ 4 down and 1 flat, stayed positive with 30 up/ 4 down and 1 flat at the mid-day, ending with a positive close of 29/4 and 2 flats

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB was down -0.03% and the XBI was up +0.02%
  • Monday, the IBB was up +0.82% and the XBI was up +2.46%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +1.39 points or +8.08% at 18.60
  • Monday was up +0.39 points or +2.32% at 17.20

 

Closing Down (10 of 18):

  • Voyager Therapeutics (VYGR -$1.48 after Monday’s +$0.68),
  • Alnylam Pharmaceuticals (ALNY -$2.23 after Monday’s +$2.32),
  • Sage Therapeutics (SAGE -$0.94),
  • Intellia Therapeutics (NTLA -$0.94 after Monday’s +$2.37),
  • Beam Therapeutics (BEAM -$0.64),
  • Chinook Therapeutics (KDNY -$0.58 after Monday’s +$0.79),
  • uniQure NV (QURE -$0.43 after Monday’s -$0.29),
  • Regenxbio (GGNX -$0.14),
  • Mesoblast (MESO -$0.13),
  • Verve Therapeutics (VERV -$0.11),

Closing Up (10 of 17):

  • Blueprint medicine (BPMC +$2.25 after Monday’s +$1.51),
  • Ionis Pharmaceuticals (IONS +$1.57 after Monday’s +$1.52),
  • CRISPR Therapeutics (CRSP +$1.40 after Monday’s +$3.67),
  • Vericel (VCEL +$0.65 after Monday’s -$2.01),
  • Fate Therapeutics (FATE +$0.24),
  • Sangamo Therapeutic (SGMO +$0.15),
  • Caribou Biosciences (CRBU +$0.15),
  • Solid Biosciences (SLDB +$0.12),
  • Precigen (PGEN +$0.09),
  • MiMedx (MDXG +$0.06)

 

Q2/23 – May

  • Tuesday closed barely positive with 17 incliners, 18 decliners and 0 flat

 

The BOTTOM LINE: I try to keep it simple … and short!

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

Is a CRASH coming, the Nasdaq rose 16.8% through the end of April …

“The BIGGEST risk to the economy – the clock is ticking for a divided U.S. Congress to raise the federal government's debt ceiling, which currently stands at over $31 trillion but risks running out of cash as soon as June 1.

“Debt-ceiling negotiations are a lose-lose for equity investors at this point, as a failure to strike a deal will lead to an immediate recession, while a deal will strain liquidity from markets as the US Treasury issues trillions in new bonds, which are newly born.” <Jose Torres, Interactive Brokers>

It ain’t over …

As I have stated, “The cell and gene therapy sector is experiencing yet another “flight of Icarus” …  since “our” universe have oscillated between gains and losses since the first of 2023!”

There is VALUE out there however, it’s about playing or betting the timing of the sector. Even as I had stated, “I wouldn’t be buying into this rally … I would be selling into this upside!”

A very appropriate quote, “You don't do well by trying to be right; it is impossible for humans. You do well by figuring out when you're wrong faster than others do.” <Nassim Nicholas Taleb>

There are clear winners — and losers — at the start of May.

The top three (3) performing in the session:

·         Tuesday: Blueprint Medicine (BPMC), Ionis Pharmaceuticals (IONS) and CRISPR Therapeutics (CRSP)

·         Monday: CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) and Alnylam Pharmaceuticals (ALNY)

While The worst three (3) in the session:

·         Tuesday: Voyager Therapeutics (VYGR), Alnylam Pharmaceuticals (ALNY), and Sage Therapeutics (SAGE)

·         Monday: uniQure NV (QURE), AxoGen (AXGN) and Generation Bio (GBIO),

 

Earnings:

RegMed Investors (RMi) Research Note: Q1/23 earnings reporting dates, net losses, cash positions and runway outcomes … https://www.regmedinvestors.com/articles/12923  -

Sector earnings season have drawn to a close …

·         One (1) net income from 34 reported to date:

 

WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.

I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.

The NO spin zone! U.S. public shareholders deserve accountability …

Biostage (OTCQB: BSTG) …

·         Tuesday closed up +$0.04 with 110 shares traded after Monday closed FLAT after Friday closed FLAT with 23 shares traded, Thursday closed FLAT with 1,220 shares traded, Wednesday closed down -$0.31 with 951 shares traded and last Tuesday closed flat with 27 shares traded <3-month average =1,488 shares>

·         Question: Review the number of shares traded … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?

·         Accumulated deficit:  $85,901 M – still NO product in sight!

 

My question that resounds, that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.